Today's VRBPAC Meeting Topic Focus

‘The 1984 Injection Committee Meeting on Already Decided Decisions.’ AKA the Vaccines and Related Biological Products Advisory Committee Meeting January 26, 2023

The outcomes of this meeting and others like it are all nearly entirely predictable. There is simply the illusion of dissent. They may as well rename this meeting:

‘The 1984 Injection Committee Meeting on Already Decided Decisions.’

Simply read the bullet points in below and guess what the findings will be coming out of this meeting. It’s not hard to figure out what’s going to happen given the uniformity of thought of those sitting on this committee.

If you only have a moment, read the parts in bold.

The key to remember is that there is only the appearance of dissent — and on these calls, typically they allow for limited discussion about concerns around safety..

But they do not take them seriously.

Further, the time for public comment is substantially limited, as they usually are, and they do not care about the public’s comments.

The January 26th VRBPAC meeting will consider questions around simplifying the composition and immunization schedules of the authorized and approved COVID-19 vaccines, the process for determining the need for recommending a periodic update to COVID-19 vaccines, and the timing for implementation of such an update. Specifically, we hope for VRBPAC members to consider the following issues during the meeting:

• Transitioning to a single vaccine composition for primary series and booster vaccination;

• Harmonizing the strain composition of all COVID-19 vaccines (mRNA, protein-based);

• Simplifying the immunization schedule for future vaccination campaigns to administer a twodose series in certain young children, and in older adults and persons with compromised immunity, and only one dose in all other individuals;

• Establishing a process for vaccine strain selection recommendations, similar in many ways to that used for seasonal influenza vaccines, based on prevailing and predicted variants that would take place by June to allow for vaccine production by September. 6

• Convening a strain selection meeting at any time in between routine periodic strain selections to address a more pathogenic escape variant.

Here’s the full FDA media for the presentation.

---

Here is a schedule of the next few meetings — probably worth paying attention to. I’m sure they’ll find a way to snooker mRNA platform gene therapies into some of these meetings.

via FDA — Advisory Committee Calendar